

1. **Rajasubramaniam Shanmugam**, Padmaja Gade, Annique Wilson-Weekes, Hamid Sayar, Attaya Suvannasankha, Chirayu Goswami, Lang Li, Sushil Gupta, Angelo A. Cardoso, Tareq Al Baghdadi, Katie J. Sargent, Larry D. Cripe, Dhananjaya V. Kalvakolanu, H. Scott Boswell (2012). A non-canonical Flt3ITD/NF- κ B signaling pathway represses *DAPK1* in acute myeloid leukemia (AML). *Clinical Cancer Research*. **18**: 360-369.
2. **Rajasubramaniam Shanmugam**, Praveen Kusumanchi, Liang Cheng, Peter Crooks, Sundar Neelakantan, Tyler Peat, James Klaunig, William Matthews, Harikrishna Nakshatri, Christopher J Sweeney (2011). A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- κ B and generating reactive oxygen species. *International Journal of Cancer* **128**: 2481–2494.
3. **Rajasubramaniam Shanmugam**, Praveen Kusumanchi, Liang Cheng, Sundar Neelakantan, Peter Crooks, William Matthews, Harikrishna Nakshatri, and Christopher J Sweeney (2010). A water soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NF- κ B and generating reactive oxygen species. *Prostate*. **70**:1074-1086
4. **Rajasubramaniam S**, Vetrichelvan Jayaprakasan, Yesim Gokmen-Polar, Stephanie Kelich, Kathy D Miller, Michele Yip-Schneider, Liang Cheng, Poornima Bhat-Nakshatri, George W Sledge, Harikrishna Nakshatri, Michael A. Miller, Timothy DeGrado, Gary D. Hutchins and Christopher J Sweeney (2006) Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. *Prostate* **66(14):1498-511**.
5. SK Sahu, S Chakrabarti, SD Roy, N Baishya, RR Reddy, S Suklabaidya, A Kumar, S Mohanty, S Maji, A Suryanwanshi, S Rajasubramaniam, M Asthana, AK Panda, SP Singh, S Ganguly, OP Shaw, AK Bichhwalia, PK Sahoo, NR Chattopadhyay, K Chatterjee, CN Kundu, AK Das, R Kannan, Zorenpuui, E Zomawia, SA Sema, YI Singh, SK Ghosh, K Sharma, BS Das and T Choudhuri^{1,7} (2016) Association of p53 codon72 Arg>Pro polymorphism with susceptibility to nasopharyngeal carcinoma : evidence from a case-control study and meta-analysis. *Oncogenesis*. 2016 May 9;5:e225. doi: 10.1038/oncsis.2016.31
6. Harsha Lad, Pawan Ghanghoria, Rajiv Yadav, Purushottam Patel, Anil Gwal, **Rajasubramaniam Shanmugam** (2017). A compound heterozygous Asian Indian inversion deletion Gy(Ay δ β)0 with β -thalassemia in Central India: A case report. *Indian J of Hematol and Blood Trans*. DOI 10.1007/s12288-017-0806-z.
7. Rajiv Yadav, Monica Lazarus#, Pawan Ghnaghoria#, MPSS Singh, RB Gupta, S Kumar, RK Sharma, **S. Rajasubramaniam** (2016) Sickle Cell Disease in Madhya Pradesh, Central India: a comparison of Clinical profile of Sickle Cell Homozygote Vs Sickle-beta thalassemia individuals. *Hematology* Oct;21(9):558-63. doi: 10.1080/10245332.2016.1148893

8. Attaya Suvannasankha, Colin D. Crean, **Rajasubramaniam S**, Sherif S. Farag, Rafat Abonour, H. Scott Bosewell and Harikrishna Nakshatri (2008). Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide; Overcoming Drug Resistance and Ameliorating the Protective Effects of the Bone Marrow Microenvironment. *Clinical Cancer Research* **14(6): 1814-1822.**
9. Amit Kumar, Sushil Kumar Sahu, Suchitra Mohanty, Sudipta Chakrabarti, Santanu Maji, R. Rajendra Reddy, Asutosh K. Jha, Chandan Goswami, Chanakya N. Kundu, **Shanmugam Rajasubramaniam**, Subhash C. Verma and Tathagata Choudhuri (2014). Kaposi Sarcoma Herpes Virus latency associated Nuclear Antigen protein release the G2/M cell cycle blocks by modulating ATM/ATR mediated checkpoint pathway. Plos One. Jun 27;9(6):e100228. doi: 10.1371/journal.pone.0100228.
10. Christopher J Sweeney, Lang Li, **Rajasubramaniam S**, Poornima Bhat-Nakshatri, Vetrichelvan Jayaprakasan, Lee Ann Baldrige, Thomas Gardner, Martin Smith, Harikrishna Nakshatri and Liang Cheng (2004). Nuclear Factor- κ B is Constitutively Activated in Prostate cancer in vitro and is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate. *Clinical Cancer Research* **10: 5501-5507**